Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Using human genetics to predict the effects and side-effects of drugs

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Remnant lipoproteins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Relation between plasma and brain lipids

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Novel genes in LDL metabolism--a comprehensive overview

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Apolipoprotein M in lipid metabolism and cardiometabolic diseases

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Apolipoprotein M and risk of type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Autosomal recessive hypercholesterolemia in a kindred of Syrian ancestry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Genetic variants in SUSD2 are associated with the risk of ischemic heart disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Genetic variation at PPP1R3B increases hepatic CT attenuation and interacts with prandial status on plasma glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE OF REVIEW: 'Genetic proxies' are increasingly being used to predict the effects of drugs. We present an up-to-date overview of the use of human genetics to predict effects and adverse effects of lipid-targeting drugs.

RECENT FINDINGS: LDL cholesterol lowering variants in HMG-Coenzyme A reductase and Niemann-Pick C1-like protein 1, the targets for statins and ezetimibe, protect against ischemic heart disease (IHD). However, HMG-Coenzyme A reductase and Niemann-Pick C1-Like Protein 1-variants also increase the risk of type 2 diabetes and gallstone disease, respectively. Mutations in proprotein convertase subtilisin kexin 9 (PCSK9), apolipoprotein B, and microsomal triglyceride transfer protein cause low LDL cholesterol and protect against IHD. In addition, mutations in apolipoprotein B and microsomal triglyceride transfer protein cause hepatic steatosis, in concordance with drugs that inhibit these targets. Both mutations in PCSK9 and PCSK9-inhibition seem without adverse effects. Mutations in APOC3 cause low triglycerides and protect against IHD, and recent pharmacological APOC3-inhibition reported major reductions in plasma triglycerides. Human genetics support that low lipoprotein(a) protects against IHD, without adverse effects, and the first trial of lipoprotein(a) inhibition reduced lipoprotein(a) up to 78%.

SUMMARY: Recent genetic studies have confirmed the efficacy of statins and ezetimibe in protecting against IHD. Results from human genetics support that several lipid-lowering drugs currently under development are likely to prove efficacious in protecting against IHD, without major adverse effects.

OriginalsprogEngelsk
TidsskriftCurrent Opinion in Lipidology
Vol/bind27
Udgave nummer2
Sider (fra-til)105-11
Antal sider7
ISSN0957-9672
DOI
StatusUdgivet - apr. 2016

ID: 49446281